Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 439.5%.

  • Aclaris Therapeutics' EBITDA Margin fell 2854200.0% to 439.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 898.93%, marking a year-over-year decrease of 7680300.0%. This contributed to the annual value of 704.39% for FY2024, which is 4237700.0% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' EBITDA Margin stood at 439.5%, which was down 2854200.0% from 865.56% recorded in Q2 2025.
  • Aclaris Therapeutics' EBITDA Margin's 5-year high stood at 2.66% during Q4 2023, with a 5-year trough of 1622.58% in Q2 2023.
  • Over the past 5 years, Aclaris Therapeutics' median EBITDA Margin value was 998.08% (recorded in 2021), while the average stood at 855.7%.
  • Examining YoY changes over the last 5 years, Aclaris Therapeutics' EBITDA Margin showed a top increase of 12218200bps in 2024 and a maximum decrease of -10491400bps in 2024.
  • Aclaris Therapeutics' EBITDA Margin (Quarter) stood at 1533.98% in 2021, then surged by 77bps to 349.12% in 2022, then surged by 99bps to 2.66% in 2023, then plummeted by -39388bps to 1051.81% in 2024, then soared by 58bps to 439.5% in 2025.
  • Its last three reported values are 439.5% in Q3 2025, 865.56% for Q2 2025, and 1013.61% during Q1 2025.